| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8047202 | CURRAX | Nasal devices |
Jul, 2023
(2 months ago) | |
| US8327844 | CURRAX | Nasal delivery method |
Oct, 2023
(4 days from now) | |
| US9119932 | CURRAX | Nasal delivery device |
Apr, 2024
(6 months from now) | |
| US7975690 | CURRAX | Nasal devices |
Aug, 2025
(1 year, 10 months from now) | |
| US8590530 | CURRAX | Nasal delivery devices |
Sep, 2025
(1 year, 11 months from now) | |
| US9108015 | CURRAX | Nasal delivery devices |
Sep, 2025
(1 year, 11 months from now) | |
| US11571531 | CURRAX | Powder delivery devices |
Feb, 2026
(2 years from now) | |
| US10124132 | CURRAX | Nasal delivery |
Mar, 2027
(3 years from now) | |
| US10398859 | CURRAX | Nasal delivery devices |
Dec, 2027
(4 years from now) | |
| US8875704 | CURRAX | Nasal administration |
Apr, 2028
(4 years from now) | |
| US10722667 | CURRAX | Nasal administration |
Dec, 2028
(5 years from now) | |
| US10076615 | CURRAX | Nasal delivery |
Jul, 2029
(5 years from now) | |
| US8550073 | CURRAX | Nasal delivery |
Oct, 2029
(6 years from now) | |
| US8899229 | CURRAX | Powder delivery devices |
Aug, 2030
(6 years from now) | |
| US9649456 | CURRAX | Nasal administration |
Oct, 2030
(7 years from now) | |
| US8978647 | CURRAX | Nasal delivery |
Dec, 2030
(7 years from now) | |
| US10478574 | CURRAX | Nasal administration |
Nov, 2033
(10 years from now) | |
| US10076614 | CURRAX | Nasal delivery devices |
Oct, 2034
(11 years from now) | |
Onzetra Xsail is owned by Currax.
Onzetra Xsail contains Sumatriptan Succinate.
Onzetra Xsail has a total of 18 drug patents out of which 1 drug patent has expired.
Expired drug patents of Onzetra Xsail are:
- US8047202
Onzetra Xsail was authorised for market use on 27 January, 2016.
Onzetra Xsail is available in powder;nasal dosage forms.
Onzetra Xsail can be used as acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; acute treatment of migraine; treatment of migraine via delivery of sumatriptan via the nasal cavity, acute treatment of migraine; treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device, method of delivering sumatriptan to a nasal cavity, method of drug delivery via the nasal cavity, treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; method of delivering sumatriptan to a nasal cavity.
The generics of Onzetra Xsail are possible to be released after 20 October, 2034.
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Method of drug delivery via the nasal cavity; Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; Acute treatment of migraine; T...
Dosage: POWDER;NASAL
ONZETRA XSAIL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic